Ryan Cohlhepp Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $20.29, for a total value of $253,625.00. Following the sale, the chief operating officer directly owned 191,641 shares of the company’s stock, valued at approximately $3,888,395.89. This trade represents a 6.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.01, for a total value of $287,625.00.
• On Monday, March 16th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.66, for a total value of $245,750.00.
• On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.16, for a total value of $315,838.72.

Bicara Therapeutics Stock Up 3.8%

Shares of BCAX stock opened at $20.03 on Wednesday. The business has a 50-day moving average price of $21.06 and a two-hundred day moving average price of $18.24. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $24.25. The firm has a market cap of $1.32 billion, a P/E ratio of -7.21 and a beta of -0.57.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). As a group, research analysts expect that Bicara Therapeutics Inc. will post -3.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC increased its holdings in Bicara Therapeutics by 26.2% during the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after purchasing an additional 692,933 shares during the period. Rock Springs Capital Management LP increased its holdings in Bicara Therapeutics by 14.0% during the 1st quarter. Rock Springs Capital Management LP now owns 489,095 shares of the company’s stock valued at $9,728,000 after purchasing an additional 60,000 shares during the period. Quantinno Capital Management LP increased its holdings in Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after purchasing an additional 2,447 shares during the period. Orbimed Advisors LLC increased its holdings in Bicara Therapeutics by 219.1% during the 1st quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock valued at $13,273,000 after purchasing an additional 458,200 shares during the period. Finally, Siren L.L.C. increased its holdings in Bicara Therapeutics by 11.2% during the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after purchasing an additional 586,001 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. Wall Street Zen lowered Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. The Goldman Sachs Group boosted their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Citigroup assumed coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating for the company. Finally, Morgan Stanley boosted their target price on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.